Get the Daily Brief
Latest Biotech News
Korsana launches with $175M to chase Alzheimer’s antibodies
Korsana Therapeutics emerged from Paragon Therapeutics with $175 million in venture backing to advance an anti‑amyloid antibody program, KRSA‑028, targeting Alzheimer’s disease. The financing was...
Sensei rescues Faeth, gains phase II oncology asset and $200M placement
Sensei Biotherapeutics announced a merger/acquisition of Faeth Therapeutics that brings Faeth’s phase II PI3K/AKT/mTOR combination asset Piktor into Sensei’s pipeline and was executed alongside a...
J&J doubles down on cell therapy: $1B+ manufacturing site planned in Pennsylvania
Johnson & Johnson announced a plan to invest more than $1 billion to build a cell therapy manufacturing facility in Pennsylvania as part of a wider effort to scale advanced‑therapy production. The...
Ocular’s Axpaxli beats low‑dose Eylea in Phase III – market questions follow
Ocular Therapeutix reported that its intravitreal TKI hydrogel Axpaxli met the superiority primary endpoint versus a low‑dose comparator of Regeneron’s Eylea in the Sol‑1 Phase III trial for wet...
AI cuts protein drug development costs: MIT model speeds yeast engineering
MIT chemical engineers unveiled an AI‑driven method to program industrial yeast strains for protein production that substantially reduces time and cost in biopharmaceutical manufacturing. The...
AI decodes yeast DNA: manufacturers chase cheaper protein drugs
MIT chemical engineers published a study introducing an AI-driven method that programs industrial yeast to produce biopharmaceutical proteins faster and at lower cost. The team trained large...
FDA backtracks: Moderna’s mRNA flu shot put back on review track
The FDA reversed an earlier refuse‑to‑file decision and agreed to review Moderna’s revised mRNA influenza vaccine submission after the company amended its filing and the agency held an internal...
Compass nears FDA bid after second pivotal psilocybin victory
Compass Pathways reported a second positive Phase III trial for its synthetic psilocybin candidate COMP‑360 in treatment‑resistant depression, enabling the company to prepare a rolling NDA and...
Novartis bets on macrocycles: $100M now, $1.7B on the table
Novartis executed a strategic partnership to license Unnatural Products’ macrocyclic peptide platform, paying $100 million upfront with the deal carrying potential payments rising to roughly $1.7...
Merck and Mayo Clinic tie up to fuse clinical data with AI discovery
Merck signed a research and development collaboration with the Mayo Clinic to integrate Mayo Clinic Platform clinical and genomic datasets with Merck’s AI‑enabled virtual cell technologies. The...
Danaher to buy Masimo for $9.9B to bulk up diagnostics
Danaher Corp. agreed to acquire Masimo for $9.9 billion in cash—about a 38.3% premium—purchasing all outstanding shares at $180 each to strengthen its diagnostics portfolio. The deal folds...
Korsana raises $175M to chase Alzheimer’s antibody slot
Korsana Biosciences launched with $175 million in financing to develop an anti‑amyloid antibody, KRSA‑028, targeting delivery across the blood‑brain barrier. The company plans a 2027 clinical...
Axpaxli meets superiority endpoint vs Eylea in Phase 3 — market reaction mixed
Ocular Therapeutix reported that Axpaxli (OTX‑TKI), a bioresorbable intravitreal hydrogel incorporating axitinib, met its primary superiority endpoint against a low‑dose Eylea comparator in the...
UCLA lipid nanoparticles insert full‑length CFTR gene in airway cells
Researchers at UCLA demonstrated a lipid nanoparticle‑based gene‑editing platform capable of precisely inserting a full‑length healthy CFTR gene into human airway cells, a step toward a universal...
Sensei rescues Faeth: reverse merger supplies new lead cancer asset and $200M
Sensei Biotherapeutics acquired Faeth Therapeutics in an all‑stock deal that effectively functions as a reverse merger and generated a $200 million private placement as part of the transaction....
FDA reverses course: will review Moderna’s flu vaccine
The U.S. Food and Drug Administration accepted Moderna’s amended application for its mRNA influenza vaccine after initially refusing to review the submission. Moderna and the agency agreed an...
Psilocybin scores again: Compass nears NDA after second Phase III win
Compass Pathways reported a second positive Phase III trial for its synthetic psilocybin candidate COMP360, achieving the primary endpoint in treatment‑resistant depression and prompting the...
Korsana launches with $175M to test anti‑amyloid Alzheimer's antibody
Korsana Biosciences announced a $175 million Series A to advance KRSA‑028, an anti‑amyloid antibody aimed at Alzheimer’s disease, and launched out of Paragon Therapeutics with plans for clinical...
Ocular’s Axpaxli tops low‑dose Eylea in Phase III – market reaction mixed
Ocular Therapeutix reported that its Axpaxli therapy met the superiority primary endpoint versus a low‑dose Eylea control in the Sol‑1 Phase III trial for wet age‑related macular degeneration,...
FDA rejects Disc’s bitopertin: CRL raises questions about surrogate endpoint use
The FDA issued a complete response letter for Disc Medicine’s bitopertin in erythropoietic protoporphyria (EPP), concluding the surrogate biomarker reductions (PPIX) did not reliably predict...